As shown in the table above, nausea, diarrhea, and vomiting are common across the class, albeit with varying frequencies depending on the specific drug and dose
Mental Health Services and Typical BCBS Coverage Status (2026) Coverage varies by plan
Inhibition and induction of glutathione S-transferases by flavonoids: possible pharmacological and toxicological consequences
Studies have shown that many patients regain a significant portion of lost weight after discontinuing GLP-1 medications, highlighting the importance of sustainable lifestyle changes alongside pharmaceutical intervention
Here's a real-world comparison of the weight loss data we have: Semaglutide 2.4 mg (Wegovy): ~15% body weight loss at 68 weeks in the STEP 1 trial Tirzepatide 15 mg (Zepbound): ~22.5% body weight loss at 72 weeks in SURMOUNT-1 Retatrutide 12 mg: ~24.2% body weight loss at 48 weeks in Phase 2 (shorter trial, remember) Promising, but still unproven at scale
Nutrition has a role in maintaining optimal blood supply to the brain